Comparative in vitro activity of gemifloxacin against gram-positive and gram-negative clinical isolates in Argentina

Diagnostic Microbiology and Infectious Disease

Volumn 40, Issue 4, 2001, Pages 187-192

  Lopez, H ^a   Stepanik, D ^a   Vilches, V ^a   Scarano, S ^a   Sarachian, B ^b   Mikaelian, G ^c   Finlay, J ^d   Sucari, A ^a  

^a Centro de Infectologia   (Argentina)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^c Centro de Estudios Microbiologicos   (Argentina)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Gemifloxacin; Gram positive and Gram negative strains; In vitro activity

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAMASE; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GEMIFLOXACIN; LEVOFLOXACIN; METICILLIN; PENICILLIN G; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARGENTINA; ARTICLE; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; HAEMOPHILUS INFLUENZAE TYPE A; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; ARGENTINA; BACTERIAL INFECTIONS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES;

EID: 0034811786     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00271-1     Document Type: Article

References (25)

1. A review of comparative in-vitro activities of 12 antimicrobials agents, with a focus on five new 'respiratory quinolones'
2. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates
3. Antimicrobial activity of LB20304, a novel. Fluoronaphthyridone
4. Antipneumococcal activities of gemifloxacin compared to those of nine other agents
5. Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States 1999
6. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of 30-center national survillance study
7. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
8. In vitro activity of trovafloxacin, a new fluorquinolone, against recent clinical isolates
9. Pneumococcal resistance in the UK
10. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci
11. A Comparative In Vitro Surveillance Study of Gemifloxacin Activities against 2,632 Recent Streptococcus pneumoniae Isolates from across Europe, North America, and South America
12. International multicenter investgation of LB20304, a new fluoronaphthyridone
13. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates
14. Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers thoughout the United States
15. Comparative in vitro activity of gemifloxacin
16. Antibiotic armaggedon
17. In Vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
18. In-vitro and in-vivo evaluations of LB-20304, a new fluoronaphthyridone
19. Activity of gatifloxacin to those of seven agents against bacteria recovered from outpatients with respiratory tract infection
20. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998
21. Survey of susceptitibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: A prospective U. S. study
22. In vitro activity of Bay 12-8039, a new fluoroquinolone